Drug Trial Radar · NCT02792218
Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis
Last checked: Nov 20, 2026Latest source record: Oct 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
930
Actual
Start
Sep 20, 2016
Primary completion
Jul 5, 2019
Study completion Jul 20, 2020
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jun 7, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To compare the efficacy and safety of ofatumumab administered subcutaneously (sc) every 4 weeks versus teriflunomide administered orally once daily in patients with relapsing multiple sclerosis
Conditions
- Relapsing Multiple Sclerosis
Interventions
Ofatumumab subcutaneous injectionDrug
Ofatumumab 20 mg pre-filled syringes for subcutaneous injection on days 1, 7, 14, week 4 and every 4 weeks thereafter
Teriflunomide-matching placebo capsulesDrug
Placebo capsule, matching in appearance to teriflunomide, taken orally once daily
Teriflunomide capsuleDrug
Teriflunomide 14 mg oral capsule taken once daily
Matching placebo of ofatumumab subcutaneous injectionsDrug
Matching placebo of ofatumumab subcutaneous injections on days 1, 7, 14, week 4 and every 4 weeks thereafter
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized Relapse Rate (ARR)Time frame: Baseline up to 2.5 years
Locations
166 sites in 29 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Phoenix, Arizona
Novartis Investigative Site
Berkeley, California
Novartis Investigative Site
Fullerton, California
Novartis Investigative Site
Sacramento, California
Novartis Investigative Site
Washington D.C., District of Columbia
Novartis Investigative Site
Atlantis, Florida
Novartis Investigative Site
Delray Beach, Florida
Novartis Investigative Site
Hollywood, Florida
Novartis Investigative Site
Loxahatchee Groves, Florida
Novartis Investigative Site
Miami, Florida
Novartis Investigative Site
Miami, Florida
Novartis Investigative Site
Naples, Florida
Novartis Investigative Site
North Palm Beach, Florida
Novartis Investigative Site
Pensacola, Florida
Novartis Investigative Site
Port Charlotte, Florida
Novartis Investigative Site
Sunrise, Florida
Novartis Investigative Site
Vero Beach, Florida
Novartis Investigative Site
West Palm Beach, Florida
Novartis Investigative Site
Savannah, Georgia
Novartis Investigative Site
Honolulu, Hawaii
Novartis Investigative Site
Chicago, Illinois
Novartis Investigative Site
Northbrook, Illinois
Novartis Investigative Site
Indianapolis, Indiana
Novartis Investigative Site
Des Moines, Iowa
Novartis Investigative Site
Kansas City, Kansas
Novartis Investigative Site
Overland Park, Kansas
Novartis Investigative Site
Alexandria, Louisiana
Novartis Investigative Site
Baton Rouge, Louisiana
Novartis Investigative Site
Clinton Township, Michigan
Novartis Investigative Site
Detroit, Michigan
Novartis Investigative Site
Golden Valley, Minnesota
Novartis Investigative Site
Chesterfield, Missouri
Novartis Investigative Site
Ozark, Missouri
Novartis Investigative Site
St Louis, Missouri
Novartis Investigative Site
Las Vegas, Nevada
Novartis Investigative Site
Latham, New York
Novartis Investigative Site
Charlotte, North Carolina
Novartis Investigative Site
Raleigh, North Carolina
Novartis Investigative Site
Winston-Salem, North Carolina
Novartis Investigative Site
Winston-Salem, North Carolina
Showing 40 of 166 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.